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Introduction {#cam41119-sec-0001}
============

Liver cancer is one of the few cancers that is increasing in incidence and mortality worldwide [1](#cam41119-bib-0001){ref-type="ref"}, including Canada [2](#cam41119-bib-0002){ref-type="ref"}, [3](#cam41119-bib-0003){ref-type="ref"}, [4](#cam41119-bib-0004){ref-type="ref"}. This is due to the growing prevalence of underlying chronic liver diseases, mainly chronic viral hepatitis, alcoholic and nonalcoholic liver disease, and the aging of the population that have those diseases [2](#cam41119-bib-0002){ref-type="ref"}, [3](#cam41119-bib-0003){ref-type="ref"}, [4](#cam41119-bib-0004){ref-type="ref"}. Hepatocellular carcinoma (HCC) accounts for the majority (\~72%) of liver cancers in both males and females in Canada [4](#cam41119-bib-0004){ref-type="ref"}. For patients with early‐stage HCC, potentially curative treatment options include radiofrequency ablation (RFA), surgical resection (SR), and liver transplantation (LT). These treatments provide survival benefits, and outcomes are optimized by identification of appropriate patients [5](#cam41119-bib-0005){ref-type="ref"}, [6](#cam41119-bib-0006){ref-type="ref"}, [7](#cam41119-bib-0007){ref-type="ref"}. Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate‐stage HCC [8](#cam41119-bib-0008){ref-type="ref"}, [9](#cam41119-bib-0009){ref-type="ref"}, [10](#cam41119-bib-0010){ref-type="ref"}. However, in clinical practice, TACE has been used as an alternative or combination therapy in patients with early‐ or advanced‐stage HCC [11](#cam41119-bib-0011){ref-type="ref"}.

HCC is associated with high costs for treatment, in particular, SR and LT, and management of the cancer presents both clinical and financial challenges [4](#cam41119-bib-0004){ref-type="ref"}, [12](#cam41119-bib-0012){ref-type="ref"}, [13](#cam41119-bib-0013){ref-type="ref"}. Facilities and resources in Canada to deal with end‐stage liver disease are generally inadequate aside from the few pockets of expertise at university‐based centers that have limited capacity [14](#cam41119-bib-0014){ref-type="ref"}. As HCC incidence increases, access to potentially curative treatments and the costs associated with them will present new challenges to the Canadian healthcare system. Important considerations include economic evaluation in general, and cost‐effectiveness analysis to help guide evidence‐based policy decision‐making in balancing health gains against the costs of interventions [15](#cam41119-bib-0015){ref-type="ref"}.

Net benefit regression framework utilizing person‐level data from administrative datasets facilitates the use of regression methods in the economic evaluation [16](#cam41119-bib-0016){ref-type="ref"}. Instead of the usual approach of aggregating cost and effect differences across different intervention strategies, the key advantage of the net benefit framework is the ability to use standard regression techniques, adjusting for explanatory variables to examine the marginal impact on incremental cost‐effectiveness [16](#cam41119-bib-0016){ref-type="ref"}. The net benefit calculation determines whether a new treatment meets (or surpasses) the decision‐maker\'s expectations of "good value for money". The results can be used to help develop policy, with an aim toward improving efficiency and value in healthcare [17](#cam41119-bib-0017){ref-type="ref"}. We aimed to evaluate the real‐world cost‐effectiveness of potentially curative and combination (including TACE combined with curative treatment) treatments in patients diagnosed with HCC over a 9‐year study time frame from a healthcare payer\'s perspective in a Canadian setting.

Materials and Methods {#cam41119-sec-0002}
=====================

Study design and population {#cam41119-sec-0003}
---------------------------

The study included all eligible HCC cases aged 18 years and older in Ontario diagnosed between January 1, 2002 and December 31, 2010 to estimate the effectiveness, cost, and cost‐effectiveness of potentially curative treatments compared with no treatment to provide an estimate of the trade‐off between extra benefit and extra cost as well as utilizing net benefit regression framework to estimate the incremental net benefit (INB). HCC cases were identified through the Ontario Cancer Registry (OCR). The International Statistical Classification of Disease and Related Health Problems, 9th Revision (ICD‐9) site code 155.0, in combination with histology codes 8170--8175 of the International Classification of Diseases for Oncology, Third Edition (ICD‐O‐3), were used to identify cases of primary liver cancer. Patients who had death dates before or on the HCC diagnosis date during the study period were excluded. Furthermore, patients who received best supportive care within the first year after HCC diagnosis and those who received palliative treatments for advanced‐stage of HCC such as sorafenib or chemotherapy over the study period were also excluded.

Data sources and study variables {#cam41119-sec-0004}
--------------------------------

The OCR is a provincial population‐based cancer registry that contains information on all new cases of cancer (except for nonmelanoma skin cancers) in Ontario since 1964 [18](#cam41119-bib-0018){ref-type="ref"}. The OCR includes data regarding date and stage of HCC diagnosis, age, sex, birth location, urban or rural residence, cause of death, and date of death. The OCR cohort was linked to the Discharge Abstract Database maintained by the Canadian Institute for Health Information, the Ontario Health Insurance Plan (OHIP), the Ontario Drug Benefit Program, and the Canadian census data, to provide person‐level information on sociodemographic, screening, treatment, and clinical factors [19](#cam41119-bib-0019){ref-type="ref"}. The OHIP is a publically funded healthcare program for all Ontario residents; physician billing claims dataset contains service and diagnosis information for outpatient visits in Ontario. The Discharge Abstract Database contains information relating to diagnosis and procedures for all hospitalizations in Ontario, frequency and type of hospital admissions, length of stay, and in‐hospital mortality. The Ontario Drug Benefit dataset contains information regarding prescription medications (including sorafenib) dispensed to all adults aged 65 years and older and those receiving social assistance. Although there are some variances in different healthcare services, the system provides free access to hospital and emergency department visits, physician services, homecare, copayments for long‐term care placements, and prescription medications for those aged 65 years and older.

Area‐level socio‐economic status was quantified using median neighborhood household income. Median neighborhood household income was determined through linking of postal codes to Canadian census data; income was categorized into quintiles corresponding to income status of neighborhoods. The least and the most well‐off 20% of neighborhoods were included within the first and the fifth quintiles, respectively [20](#cam41119-bib-0020){ref-type="ref"}. Where possible, hospitalization records from the date of diagnosis were used to assign each patient and control subject a baseline Charlson--Deyo comorbidity index. If patients did not have a hospitalization record at their diagnosis date, baseline comorbidity was determined by looking back 2 years into the hospitalization data to find the most recent hospitalization record; the comorbidity score from that hospitalization was then applied [12](#cam41119-bib-0012){ref-type="ref"}, [13](#cam41119-bib-0013){ref-type="ref"}, [20](#cam41119-bib-0020){ref-type="ref"}, [21](#cam41119-bib-0021){ref-type="ref"}. The Charlson--Deyo comorbidity index at baseline was marked as "missing" if the individual had no hospitalization records at diagnosis or during the 2 years before diagnosis. Comorbidity was adjusted for each hospitalization after baseline. The Charlson--Deyo comorbidity index was calculated using methods previously described [22](#cam41119-bib-0022){ref-type="ref"}, [23](#cam41119-bib-0023){ref-type="ref"}; an ICD‐10 coding algorithm was applied to the diagnostic field codes from the hospitalization data (excluding diagnoses for liver disease, metastatic cancer, diabetes, and HIV). Conditions were weighted and then summed up to provide an overall comorbidity index value for a given episode, which was then categorized into one of five groups (0, 1, 2, ≥3, or no hospitalization record) representing different degrees of comorbidity.

Patients diagnosed with diabetes, HIV, and covariates that denote liver disease stage measured before HCC diagnosis were identified from the Discharge Abstract Database and OHIP using ICD‐9 and ICD‐10 codes. The study also included viral hepatitis cases identified through OHIP data; defined as subjects having at least two viral hepatitis visits (OHIP diagnostic code "070") within the 4‐year interval before the HCC diagnosis date---to cover as much available OHIP data as possible. Indicators of liver disease stage were categorized exclusively as: (1) viral hepatitis; (2) no cirrhosis; (3) cirrhosis; (4) alcoholic liver disease (ALD) + cirrhosis; (5) viral hepatitis + cirrhosis; (6) ALD + viral hepatitis + cirrhosis; (7) decompensated cirrhosis (i.e., cirrhosis and any recorded ascites, esophageal varices, or hepatic encephalopathy); (8) ALD + decompensated cirrhosis; (9) nonalcoholic fatty liver disease (NAFLD) + decompensated cirrhosis; (10) viral hepatitis + decompensated cirrhosis; and (11) ALD + viral hepatitis + decompensated cirrhosis. Other relevant variables (including ALD alone, NAFLD alone, etc.) which were \<20 in total were not considered as covariates.

To identify patients who received screening ultrasonography, we identified all abdominal ultrasonography performed on patients before HCC diagnosis utilizing OHIP fee codes [21](#cam41119-bib-0021){ref-type="ref"}. We obtained exclusive data regarding receipt of abdominal ultrasound screening (at least 4.5 months apart from previous ultrasound), which was defined as receiving one or more ultrasound screening annually for 2 years before HCC diagnosis (i.e., routine screening), at least one screen either within 12 months or between 12 and 24 months before HCC diagnosis (i.e., inconsistent screening), and no screening before HCC diagnosis.

HCC treatment strategies {#cam41119-sec-0005}
------------------------

HCC treatments were identified from the Discharge Abstract Database, OHIP, and Ontario Drug Benefit databases determining the timing; for example, if both Discharge Abstract Database and OHIP for SR exits, we considered only the first SR. Mutually exclusive potentially curative monotherapies and combination therapies with palliative treatment (TACE) for HCC considered include: (i) RFA monotherapy; (ii) SR monotherapy; (iii) LT monotherapy; (iv) RFA plus SR; (v) RFA plus LT; (vi) SR plus LT; (vii) TACE plus RFA; (viii) TACE plus SR; (ix) TACE plus LT; (x) RFA plus SR plus LT triple treatment; and (xi) no treatment. Procedure codes used to identify diabetes, HIV, indicators of liver disease stage, HCC screening, and treatments can be found in the Tables [S1](#cam41119-sup-0005){ref-type="supplementary-material"} and [S2](#cam41119-sup-0005){ref-type="supplementary-material"} [12](#cam41119-bib-0012){ref-type="ref"}, [20](#cam41119-bib-0020){ref-type="ref"}, [21](#cam41119-bib-0021){ref-type="ref"}.

Measuring effectiveness {#cam41119-sec-0006}
-----------------------

Life expectancy for each age in this study is the estimated average period that a person may expect to live, according to the age‐specific mortality rates for all causes. Potential years of life lost (PYLL, a measure of premature mortality) and quality‐adjusted life years lost (QALYL) were used to measure effectiveness. This study followed patients according to their death status until the end of year 2011. For those who died in or before 2011, age at death was calculated by adding years between diagnosis and death to the age at diagnosis. The age at diagnosis was recorded in the OCR cd‐link data as a categorical variable: below 60, 60--69, 70--79, or 80 years and above, which was assumed to be 55, 65, 75, or 85 years, respectively, in our analysis. To estimate age at death for patients who were still alive by the end of 2011, we first calculated the expected year of death based on the year of HCC diagnosis and the expected length of survival (i.e., period from diagnosis to death) according to stage at diagnosis; the estimate of survival was derived from the published literature (e.g., early‐stage I: 5 years; intermediate‐stage II: 4 years; and advanced‐stage III or IV: 3 years survival) [24](#cam41119-bib-0024){ref-type="ref"}, [25](#cam41119-bib-0025){ref-type="ref"}. If the expected year of death was 2011 or earlier, given the patient was still alive by the end of 2011, we assumed 2012 to be the most likely year of death. Accordingly, age at death could be estimated based on age at diagnosis and years between death and diagnosis. Subsequently, PYLL for each patient was determined using Ontario life tables which provided the standard life expectancy based on sex and age at death of an individual person [26](#cam41119-bib-0026){ref-type="ref"}.

QALYL consisted of two parts: (1) the PYLL was weighted by the average health state utility should the person be still alive and without disease; and (2) the number of years between diagnosis and death weighted by the quality of life according to the disease stage (from normal utility to utility of disease stage: noncirrhosis, compensated cirrhosis, decompensated cirrhosis, post‐LT or surgery in year 2 and onwards, and incurable HCC). The pooling of utility values for each stage (except incurable HCC = 0.40 \[range: 0.32--0.48\]) [27](#cam41119-bib-0027){ref-type="ref"} was attempted using different preference‐based measures; these provide similar results by random effects models, and the estimates appeared to be close to other studies that provided input into decision‐analytic models [27](#cam41119-bib-0027){ref-type="ref"}, [28](#cam41119-bib-0028){ref-type="ref"}, [29](#cam41119-bib-0029){ref-type="ref"}. Although we developed the year‐specific model and considered treating stage as time‐dependent, only stage at diagnosis was available in the database; we could not obtain data regarding whether patients progressed beyond their disease stage at diagnosis. Pooled mean health state utilities of disease stage from published literature for base case analysis and the lower and upper bounds for sensitivity analyses are shown in Tables [S3](#cam41119-sup-0005){ref-type="supplementary-material"}A--D.

Measuring costs {#cam41119-sec-0007}
---------------

Full details of data sources and estimation of direct health care costs associated with HCC has been previously published [12](#cam41119-bib-0012){ref-type="ref"}, [13](#cam41119-bib-0013){ref-type="ref"}. The total costs of healthcare services included outpatient visits, emergency department visits, acute inpatient hospitalizations, same‐day surgery, prescription medications, homecare visits, continuing care, and long‐term care. Costs associated with outpatient physician visits and laboratory tests in Ontario were estimated from the Physician Claims History Database of the OHIP. Costs for emergency department visits and same‐day surgery were estimated using the National Ambulatory Care Reporting System database [30](#cam41119-bib-0030){ref-type="ref"}. The costs of hospitalization, emergency department visits, and same‐day surgery for a particular year were estimated using the Resource Intensity Weight methodology developed by the Canadian Institute for Health Information [30](#cam41119-bib-0030){ref-type="ref"}. Prescription medication costs were obtained from the Ontario Drug Benefit Program [30](#cam41119-bib-0030){ref-type="ref"}. Costs associated with home care, continuing care, and long‐term care were estimated from the Ontario Home Care database, Continuing Care Reporting System, and Ontario Drug Benefit Program. Costs were adjusted for inflation to 2013 Canadian dollars using the Statistics Canada Consumer Price Index for healthcare and personal items for Ontario [31](#cam41119-bib-0031){ref-type="ref"}. Purchasing Power Parity for Gross Domestic Product was used to convert 2013 Canadian dollars to 2013 US dollars [32](#cam41119-bib-0032){ref-type="ref"}. Effects and costs were discounted at 3% annually as a base case to capture time preference given somewhat variation in the follow‐up time [33](#cam41119-bib-0033){ref-type="ref"}.

Statistical analysis {#cam41119-sec-0008}
--------------------

Multiple imputation was used to impute values for variables with a high degree of missing data such as cancer stage at HCC diagnosis, birth country, and Charlson--Deyo comorbidity index. Five independent draws from an imputation model were used to create five completed datasets and results were combined to obtain one imputation inference [34](#cam41119-bib-0034){ref-type="ref"}. Statistically, multiple imputation is an established method to deal with replacing each missing value with a set of plausible values to ensure that the results are unbiased and capture the appropriate degree of precision [34](#cam41119-bib-0034){ref-type="ref"}. Multiple Imputation procedure by logistic regression was used in a sequential process to generate monotone patterns (PROC MI with LOGISTIC in the MONOTONE statement) [35](#cam41119-bib-0035){ref-type="ref"}, [36](#cam41119-bib-0036){ref-type="ref"}.

Next, we used the net benefit regression framework [16](#cam41119-bib-0016){ref-type="ref"} to evaluate the real‐world cost‐effectiveness of curative treatments of HCC compared with no treatment among patients diagnosed with HCC from 2002 to 2010. In the first step, the net benefit value for each person (*NB* ~*i*~) was calculated using the formula: willingness‐to‐pay (*λ*)\**E* ~*i*~−*C* ~*i*~, where *E* ~*i*~ is the observed incremental effect (i.e., life year \[LY\] or quality‐adjusted life year \[QALY\] gained) and *C* ~*i*~ is the incremental cost, for the *i*th person. Various values of *λ* for an additional effect [16](#cam41119-bib-0016){ref-type="ref"} were explored ranging from \$0 to \$500,000. *NB* ~*i*~ differs by various levels of *λ*; therefore, the person‐level net benefit is denoted as *NB(λ)* ~*i*~.

The net benefit regression (i.e., multiple linear regression) involved fitting a linear regression model while adjusting for the relevant covariates (dummy variables), including sociodemographic characteristics: age (\<60, 60--69, 70--79, ≥80 years), sex (male, female), income quintile (Q1‐lowest to Q5‐highest), residence (urban, rural), birth country (Canada, outside of Canada); clinical characteristics: Charlson--Deyo comorbidity index (0, 1, 2, ≥3), diabetes, HIV, liver disease stage, receipt of ultrasound screening 2 years before HCC diagnosis (routine screening, inconsistent screening, no screening), stage at diagnosis (early‐stage I, intermediate‐stage II, advanced‐stage III‐IV), and index year of HCC diagnosis (2002--2004, 2005--2007, 2008--2010). Additionally, we adjusted for propensity score to minimize bias related to the nonrandom allocation of potential curative treatment [37](#cam41119-bib-0037){ref-type="ref"}, [38](#cam41119-bib-0038){ref-type="ref"}. The propensity score for an individual is the conditional probability of assignment to having a curative treatment of HCC given the observed individual covariates. Here, it was derived by fitting a logistic regression model with HCC curative treatment as the dependent variable and the aforementioned covariates as independent variables. This approach allows for the adjustment of how covariates may affect the estimate of the intervention\'s INB (i.e., the marginal impact on incremental cost‐effectiveness, ICER) [16](#cam41119-bib-0016){ref-type="ref"}. The regression coefficient δ on the treatment dummy provides the estimate of the INB of treatment versus no treatment corresponding to a certain level of *λ* adjusted for the covariates. Treatment is defined to be cost‐effective, at a certain level of *λ*, if the corresponding INB is positive (i.e., INB \>0).

Threshold values of the variance inflation factors were evaluated in the context of several other factors that influence the variance of regression coefficients [39](#cam41119-bib-0039){ref-type="ref"}. We eliminated interaction terms if there was no statistical significance or if the variance inflation factor values exceed 10 (i.e., indicating severe multicollinearity), which can reduce the variance of the regression coefficients. All covariates were included in the model because they were considered to be significant correlates of the outcome (theoretical justification) or were significantly different between the treatments (statistical validation).

The final step was assessing uncertainties and constructing cost‐effectiveness acceptability curves (CEACs) using the coefficient estimates of the treatment (*T*) variable and *P*‐values obtained from the net benefit regression model [16](#cam41119-bib-0016){ref-type="ref"}, [40](#cam41119-bib-0040){ref-type="ref"}. CEACs have been widely adopted as a method to quantify and incorporate the uncertainty that exists around the estimates of expected costs and expected effects associated with the interventions. A CEAC shows the probability that an intervention is cost‐effective compared with the alternative, given the observed data, for a range of *λ* values that a decision‐maker might be willing to pay for a particular unit change in the outcome (i.e., LY and QALY) [16](#cam41119-bib-0016){ref-type="ref"}, [40](#cam41119-bib-0040){ref-type="ref"}. The *P*‐values obtained from the net benefit regression are two‐sided but only one‐sided values are needed to test whether the INB is positive (i.e., treatment is cost‐effective) or negative (i.e., treatment is not cost‐effective) at the specified *λ*; therefore, the regression two‐sided *P*‐values are divided by two [16](#cam41119-bib-0016){ref-type="ref"}. For negative INB, the probability that the treatment is preferred equals the one‐sided *P*‐value, and for positive incremental net‐benefits, the probability that the treatment is preferred equals 1 minus the one‐sided *P*‐value [16](#cam41119-bib-0016){ref-type="ref"}. A CEAC was created by plotting a graphical representation that the HCC curative treatment is cost‐effective compared with no treatment (*y*‐axis), as a function of societal *λ* threshold per additional LY or QALY for a range of *λ* between \$0 and \$100,000 (*x*‐axis).

Analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC) and STATA version 12.0 (Stata Corporation, College Station, TX) statistical software applications.

Ethics approval {#cam41119-sec-0009}
---------------

Ethics approval for the study was granted by the University of Toronto Health Sciences Research Ethics Board. Informed consent was not obtained because this secondary analysis accessed existing de‐identified data; consent was therefore deemed to be neither feasible nor necessary.

Results {#cam41119-sec-0010}
=======

Description of cohort {#cam41119-sec-0011}
---------------------

Overall, 3,857 patients were identified as having a primary diagnosis of HCC from the OCR between 2002 and 2010. Flowchart of study population can be found in Figure [S1](#cam41119-sup-0001){ref-type="supplementary-material"}. The final study cohort comprised 2,222 patients diagnosed with HCC after excluding 1,154 patients who had best supportive care within 1 year after HCC diagnosis, and 481 patients who had palliative treatments (chemotherapy and sorafenib) during the study period. The median and mean (standard deviation) of follow‐up time of patients diagnosed with HCC were 489 days and 735 (772) days, respectively. Overall baseline characteristics for this cohort are summarized in Table [S4](#cam41119-sup-0005){ref-type="supplementary-material"} and those stratified by treatment are summarized in Table [1](#cam41119-tbl-0001){ref-type="table-wrap"}. The majority (*n*= 1,182, 53.2%) of patients diagnosed with HCC did not receive curative treatment. Overall, 34.9% (*n*= 775) received a single curative treatment (10.5% received RFA, 14.1% SR and 10.3% LT monotherapy), 10.2% (*n*= 227) received dual treatments (3.1% received RFA plus SR, 2.5% RFA plus LT, 1.7% SR plus LT, 1.2% TACE plus RFA, 0.5% TACE plus SR, and 1.2% TACE plus LT), and 0.5% (*n*= 12) received triple treatments (RFA plus SR plus LT) during the study period.

###### 

Baseline characteristics of patients with hepatocellular carcinoma by type of treatment, 2002--2010

  Variable                                                          Monotherapy   Dual treatments   Triple treatments                                                                          
  --------------------------------------------------- ------------- ------------- ----------------- ------------------- ----------- ----------- ----------- ----------- ---------- ----------- -----------
  Overall                                             1182 (53.2)   234 (10.5)    313 (14.1)        228 (10.3)          69 (3.1)    55 (2.5)    37 (1.7)    27 (1.2)    12 (0.5)   27 (1.2)    12 (0.5)
  Age group (years)                                                                                                                                                                            
  \<60                                                320 (27.1)    66 (28.2)     114 (36.4)        170 (74.6)          20 (29.0)   35 (63.6)   23 (62.2)   6 (22.2)    6 (50.0)   17 (63.0)   10 (83.3)
  60--69                                              304 (25.7)    65 (27.8)     79 (25.2)         58 (25.4)           22 (31.9)   19 (34.6)   14 (37.8)   6 (22.2)    --         10 (37.0)   --
  70--79                                              367 (31.1)    85 (36.3)     104 (33.2)        0                   22 (31.9)   --          0           14 (51.9)   --         0           0
  80 +                                                191 (16.2)    18 (7.7)      16 (5.1)          0                   --          0           0           --          --         0           0
  Sex                                                                                                                                                                                          
  Female                                              275 (23.3)    60 (25.6)     72 (23.0)         33 (14.5)           12 (17.4)   6 (10.9)    7 (18.9)    10 (37.0)   --         --          --
  Male                                                907 (76.7)    174 (74.4)    241 (77.0)        195 (85.5)          57 (82.6)   49 (89.1)   30 (81.1)   17 (63.0)   9 (75.0)   26 (96.3)   10 (83.3)
  Income quintile                                                                                                                                                                              
  Q1 (lowest)                                         322 (27.2)    56 (23.9)     55 (17.6)         52 (22.8)           14 (20.3)   13 (23.6)   --          --          --         7 (25.9)    --
  Q2                                                  247 (20.9)    52 (22.2)     70 (22.4)         42 (18.4)           17 (24.6)   12 (21.8)   7 (18.9)    --          --         9 (33.3)    --
  Q3                                                  244 (20.6)    45 (19.2)     69 (22.0)         48 (21.1)           14 (20.3)   9 (16.4)    9 (24.3)    --          --         --          --
  Q4                                                  173 (14.6)    38 (16.2)     69 (22.0)         45 (19.7)           14 (20.3)   12 (21.8)   10 (27.0)   9 (33.3)    --         --          --
  Q5 (highest)                                        185 (15.7)    42 (18.0)     50 (16.0)         41 (18.0)           9 (13.0)    9 (16.4)    6 (16.2)    --          0          6 (22.2)    0
  Missing                                             11 (0.9)      --            0                 0                   --          0           0           0           0          0           0
  Residence                                                                                                                                                                                    
  Urban                                               1061 (89.8)   220 (94.0)    288 (92.0)        207 (90.8)          67 (97.1)   52 (94.6)   33 (89.2)   27 (100)    12 (100)   26 (96.3)   12 (100)
  Rural                                               118 (10.0)    14 (6.0)      25 (8.0)          21 (9.2)            --          --          --          0           0          --          0
  Missing                                             --            0             0                 0                   0           0           0           0           0          0           0
  Birth country                                                                                                                                                                                
  Other                                               537 (45.4)    49 (20.9)     77 (24.6)         34 (14.9)           10 (14.5)   --          --          8 (29.6)    8 (66.7)   --          --
  Canada                                              533 (45.1)    66 (28.2)     66 (21.1)         32 (14.0)           13 (18.8)   --          --          7 (25.9)    --         0           --
  Unknown/missing                                     112 (9.5)     119 (50.9)    170 (54.3)        162 (71.1)          46 (66.7)   48 (87.3)   27 (73.0)   12 (44.4)   --         25 (92.6)   9 (75.0)
  Comorbidity                                                                                                                                                                                  
  0                                                   404 (34.2)    101 (43.2)    139 (44.4)        67 (29.4)           27 (39.1)   24 (43.6)   6 (16.2)    11 (40.7)   8 (66.7)   8 (29.6)    --
  1                                                   266 (22.5)    74 (31.6)     89 (28.4)         100 (43.9)          22 (31.9)   21 (38.2)   21 (56.8)   8 (29.6)    --         13 (48.2)   7 (58.3)
  2                                                   138 (11.7)    27 (11.5)     36 (11.5)         29 (12.7)           14 (20.3)   --          10 (27.0)   --          --         --          --
  3 +                                                 100 (8.5)     24 (10.3)     27 (8.6)          25 (11.0)           --          --          0           --          0          --          0
  No hospitalization record                           274 (23.2)    8 (3.4)       22 (7.0)          7 (3.1)             --          --          0           0           0          0           0
  Diabetes                                            550 (46.5)    121 (51.7)    137 (43.8)        149 (65.4)          40 (58.0)   31 (56.4)   30 (81.1)   13 (48.2)   --         20 (74.1)   7 (58.3)
  HIV                                                 22 (1.9)      9 (3.9)       --                6 (2.6)             --          --          --          --          0          0           --
  Indicators of liver disease stage                                                                                                                                                            
  Viral hepatitis                                     35 (3.0)      --            10 (3.2)          0                   --          0           0           0           0          0           0
  No cirrhosis                                        277 (23.4)    16 (6.8)      102 (32.6)        0                   17 (24.6)   0           0           0           0          0           0
  Cirrhosis                                           205 (17.3)    45 (19.2)     81 (25.9)         24 (10.5)           18 (26.1)   8 (14.6)    9 (24.3)    10 (37.0)   7 (58.3)   10 (37.0)   --
  ALD + cirrhosis                                     41 (3.5)      13 (5.6)      6 (1.9)           --                  --          --          0           0           0          0           0
  Viral hepatitis + cirrhosis                         38 (3.2)      10 (4.3)      18 (5.8)          --                  --          --          --          0           0          0           --
  ALD + Viral hepatitis + cirrhosis                   6 (0.5)       --            --                0                   --          --          0           --          0          0           0
  Decompensated cirrhosis                             288 (24.4)    70 (29.9)     61 (19.5)         85 (37.3)           12 (17.4)   18 (32.7)   14 (37.8)   11 (40.7)   --         12 (44.4)   6 (50.0)
  ALD + decompensated cirrhosis                       159 (13.5)    44 (18.8)     7 (2.2)           66 (29.0)           --          16 (29.1)   7 (18.9)    --          0          --          0
  NAFLD + decompensated cirrhosis                     8 (0.7)       --            0                 --                  --          0           --          0           0          --          0
  Viral hepatitis + decompensated cirrhosis           53 (4.5)      14 (6.0)      12 (3.8)          19 (8.3)            --          --          --          --          --         0           0
  ALD + viral hepatitis + decompensated cirrhosis     47 (4.0)      9 (3.9)       --                15 (6.6)            --          --          0           --          0          0           0
  Ultrasound screening 2 years before HCC diagnosis                                                                                                                                            
  No screening                                        622 (52.6)    86 (36.8)     125 (39.9)        113 (49.6)          24 (34.8)   24 (43.6)   9 (24.3)    9 (33.3)    --         6 (22.2)    --
  Inconsistent screening                              464 (39.3)    98 (41.9)     138 (44.1)        93 (40.8)           34 (49.3)   21 (38.2)   20 (54.1)   12 (44.4)   --         19 (70.4)   6 (50.0)
  ≥1 screens annually                                 96 (8.1)      50 (21.4)     50 (16.0)         22 (9.7)            11 (15.9)   10 (18.2)   8 (21.6)    6 (22.2)    --         --          --
  Stage at HCC diagnosis                                                                                                                                                                       
  Early (stage I)                                     66 (5.6)      62 (26.5)     65 (20.8)         35 (15.4)           18 (26.1)   12 (21.8)   6 (16.2)    8 (29.6)    --         6 (22.2)    --
  Intermediate (stage II)                             83 (7.0)      45 (19.2)     48 (15.3)         55 (24.1)           16 (23.2)   24 (43.6)   7 (18.9)    11 (40.7)   --         13 (48.2)   --
  Advanced (stage III--IV)                            274 (23.2)    10 (4.3)      51 (16.3)         12 (5.3)            6 (8.7)     --          --          --          --         --          0
  Unknown                                             759 (64.2)    117 (50.0)    149 (47.6)        126 (55.3)          29 (42.0)   17 (30.9)   22 (59.5)   7 (25.9)    --         --          6 (50.0)
  Year of HCC diagnosis                                                                                                                                                                        
  2002                                                128 (10.8)    --            34 (10.9)         15 (6.6)            --          --          --          0           --         0           --
  2003                                                106 (9.0)     10 (4.3)      33 (10.5)         23 (10.1)           7 (10.1)    0           --          --          --         0           --
  2004                                                142 (12.0)    6 (2.6)       23 (7.4)          29 (12.7)           6 (8.7)     --          7 (18.9)    --          --         --          0
  2005                                                135 (11.4)    14 (6.0)      47 (15.0)         28 (12.3)           --          --          --          --          --         --          --
  2006                                                141 (11.9)    22 (9.4)      29 (9.3)          38 (16.7)           9 (13.0)    --          6 (16.2)    --          --         6 (22.2)    0
  2007                                                142 (12.0)    19 (8.1)      34 (10.9)         32 (14.0)           7 (10.1)    6 (10.9)    --          --          0          --          --
  2008                                                109 (9.2)     46 (19.7)     25 (8.0)          23 (10.1)           13 (18.8)   18 (32.7)   --          6 (22.2)    0          --          0
  2009                                                137 (11.6)    56 (23.9)     45 (14.4)         21 (9.2)            10 (14.5)   10 (18.2)   0           --          --         --          --
  2010                                                142 (12.0)    59 (25.2)     43 (13.7)         19 (8.3)            9 (13.0)    12 (21.8)   --          7 (25.9)    0          --          0

"--", counts less than six have been suppressed.

RFA, radiofrequency ablation; SR, surgical resection; LT, liver transplantation; HCC, hepatocellular carcinoma.
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With regard to dual treatments with RFA, 46 (67%) patients underwent primary SR; with LT, 52 (95%) underwent primary RFA, 12 (32%) underwent primary SR, and 27 (100%) underwent primary TACE; with TACE, 17 (63%) underwent primary RFA and 12 (100%) underwent primary SR. Of the 2,222 patients, 13.0% were stage I, 14.2% stage II, 13.0% stage III, 3.7% stage IV, and 56.2% unknown stage at diagnosis. Patients with unknown stage were less likely to have received curative treatments. Age (except RFA + SR and TACE + SR), birth country (except SR and TACE + RFA), Charlson--Deyo comorbidity index (except TACE + RFA, TACE + SR, TACE + LT, and RFA + SR + LT), liver disease stage (except SR + LT, TACE + RFA, TACE + LT, and RFA + SR + LT), and cancer stage (except SR + LT, TACE + SR, and RFA + SR + LT) were associated with receipt of curative treatments (*P *\< 0.05); additionally, sex was associated with receipt of LT, RFA + LT or TACE + LT (*P *\< 0.05), diabetes was associated with receipt of SR, LT, SR + LT or TACE + LT (*P *\< 0.05), ultrasound screening was associated with receipt of RFA, SR, SR + LT or TACE + LT (*P *\< 0.05), and year of HCC diagnosis was associated with receipt of RFA, SR, LT, RFA + LT or RFA + SR + LT (*P *\< 0.05).

Healthcare effects and costs {#cam41119-sec-0012}
----------------------------

Effects and costs stratified by treatment strategies are summarized in Table [2](#cam41119-tbl-0002){ref-type="table-wrap"}. The lowest QALYL was among those who received RFA + SR (9.1, 95% confidence interval \[CI\]: 8.8--9.5) and the highest QALYL were among those who received LT (11.9, 95% CI: 11.7--12.0) or RFA + LT (11.8, 95% CI: 11.6--12.1). The lowest costs were among those who did not receive treatment (\$38,472, 95% CI: \$37,255--\$39,689) followed by those who received TACE + RFA (\$48,485, 95% CI: \$43,663--\$53,307), and RFA monotherapy (\$55,925, 95% CI: \$52,123--\$59,727); and the highest costs were among those who received SR + LT (\$222,275, 95% CI: \$205,992--\$238,558) or RFA + SR + LT (\$208,484, 95% CI: \$190,385--\$226,582).

###### 

Healthcare effects and costs after diagnosis of hepatocellular carcinoma by treatment strategies, 2002--2010

  Treatment strategies            Effects (mean, 95% CI)       Costs[a](#cam41119-note-0005){ref-type="fn"} (mean, 95% CI)   
  ------------------------------- ---------------------------- ------------------------------------------------------------- ----------------------------------
  No treatment (*n*= 5910)        11.2251 (11.1105--11.3397)   10.1149 (10.009--10.2207)                                     \$38,472 (\$37,255--\$39,689)
  Monotherapy                                                                                                                
  RFA (*n*= 1170)                 10.2246 (9.9959--10.4534)    9.8759 (9.6697--10.0821)                                      \$55,925 (\$52,123--\$59,727)
  SR (*n*= 1565)                  10.0818 (9.8927--10.2709)    9.9144 (9.7466--10.0822)                                      \$119,032 (\$115,799--\$122,265)
  LT (*n*= 1140)                  11.9376 (11.7841--12.0911)   11.8696 (11.7471--11.992)                                     \$211,286 (\$203,566--\$219,007)
  Dual treatments                                                                                                            
  TACE plus RFA (*n*= 135)        9.6379 (8.979--10.2968)      9.3606 (8.7722--9.9489)                                       \$48,485 (\$43,663--\$53,307)
  RFA plus SR (*n*= 345)          9.0966 (8.6997--9.4934)      9.1399 (8.7844--9.4953)                                       \$109,927 (\$103,953--\$115,902)
  TACE plus SR (*n*= 60)          11.4624 (10.4676--12.4573)   10.999 (10.0909--11.907)                                      \$126,514 (\$114,451--\$138,577)
  RFA plus LT (*n*= 275)          12.0635 (11.7867--12.3402)   11.8248 (11.5797--12.0699)                                    \$155,898 (\$144,119--\$167,677)
  TACE plus LT (*n*= 135)         11.4675 (11.0773--11.8578)   11.4621 (11.1359--11.7883)                                    \$178,354 (\$163,494--\$193,215)
  SR plus LT (*n*= 185)           10.756 (10.3731--11.1388)    10.8734 (10.5621--11.1847)                                    \$222,275 (\$205,992--\$238,558)
  Triple treatments                                                                                                          
  RFA plus SR plus LT (*n*= 60)   11.1088 (10.3933--11.8242)   11.2472 (10.6504--11.844)                                     \$208,484 (\$190,385--\$226,582)

RFA, radiofrequency ablation; SR, surgical resection; LT, liver transplantation; PYLL, potential years of life lost (a measure of premature mortality); QALYL, quality‐adjusted life years lost.

All costs reflect 2013 US\$ per person. Multiple imputation by logistic regression was used to generate missing data (cancer stage at HCC diagnosis, birth country, and Charlson--Deyo comorbidity index) for outcomes.
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Net benefit regression {#cam41119-sec-0013}
----------------------

Compared with no treatment (adjusted for important covariates), LT‐related treatments were estimated to yield more units of QALYs (incremental QALYs: RFA + SR + LT=2.72; SR + LT=2.41; LT monotherapy=2.09; RFA + LT=1.88; and TACE + LT=1.81); but more costly (\$164,608, \$173,575, \$160,430, \$112,411, and \$132,266, respectively) than RFA + SR, SR monotherapy, TACE + RFA, RFA monotherapy or TACE + SR (incremental QALYs: 1.47, 1.03, 0.93, 0.88, and 0.44, respectively; incremental costs: \$71,559, \$81,514, \$2,304, \$13,697, and \$96,088, respectively)(Table [3](#cam41119-tbl-0003){ref-type="table-wrap"}). In Figure [1](#cam41119-fig-0001){ref-type="fig"}A and B plot of incremental LYs and QALYs and costs of curative treatments relative to lowest cost scenario (no treatment), TACE plus RFA, RFA monotherapy, and RFA + SR dual treatment below the line (dotted diagonal line representing the ceiling ratio) appeared to be acceptable.

###### 

Effects, costs, and incremental cost‐effectiveness ratios of potentially curative treatment strategies for hepatocellular carcinoma compared with no treatment, 2002--2010: net benefit regression

  Treatment strategies   Average total effect (PYLL)   Average total effect (QALYL)   Average total cost (\$)   Adj incr effect[a](#cam41119-note-0008){ref-type="fn"} (LYs)   Adj incr effect^\`^ [a](#cam41119-note-0008){ref-type="fn"} (QALYs)   Adj incr cost (\$)[b](#cam41119-note-0009){ref-type="fn"}   Adj ICER (\$/LY gained)   Adj ICER (\$/QALY gained)
  ---------------------- ----------------------------- ------------------------------ ------------------------- -------------------------------------------------------------- --------------------------------------------------------------------- ----------------------------------------------------------- ------------------------- ---------------------------
  No treatment           11.2251                       10.1149                        \$38,472                                                                                                                                                                                                                                             
  TACE plus RFA          9.6379                        9.3606                         \$48,485                  1.82717                                                        0.93455                                                               \$2,304                                                     \$1,261                   \$2,465
  RFA                    10.2246                       9.8759                         \$55,925                  1.72958                                                        0.88067                                                               \$13,697                                                    \$7,919                   \$15,553
  RFA plus SR            9.0966                        9.1399                         \$109,927                 2.63641                                                        1.46756                                                               \$71,559                                                    \$27,143                  \$48,761
  SR                     10.0818                       9.9144                         \$119,032                 1.97368                                                        1.02540                                                               \$81,514                                                    \$41,301                  \$79,495
  TACE plus SR           11.4624                       10.999                         \$126,514                 1.09491                                                        0.44091                                                               \$96,088                                                    \$87,759                  \$217,932
  RFA plus LT            12.0635                       11.8248                        \$155,898                 3.01967                                                        1.88475                                                               \$112,411                                                   \$37,226                  \$59,642
  TACE plus LT           11.4675                       11.4621                        \$178,354                 3.04816                                                        1.81332                                                               \$132,266                                                   \$43,392                  \$72,941
  RFA plus SR plus LT    11.1088                       11.2472                        \$208,484                 4.10809                                                        2.71620                                                               \$164,608                                                   \$40,069                  \$60,602
  LT                     11.9376                       11.8696                        \$211,286                 3.34719                                                        2.09062                                                               \$160,430                                                   \$47,930                  \$76,738
  SR plus LT             10.756                        10.8734                        \$222,275                 3.76051                                                        2.41171                                                               \$173,575                                                   \$46,157                  \$71,972

Values are expressed as the mean. All costs reflect 2013 US\$ per person.

RFA, radiofrequency ablation; SR, surgical resection; LT, liver transplantation; PYLL, potential years of life lost; QALYL, quality‐adjusted life years lost; LY, life year.

Incremental effect is calculated as treatment effect minus no treatment effect, adjusted for relevant covariates (dummy variables), including age, sex, income quintile, urban/rural residence, birth country, Charlson--Deyo comorbidity index, diabetes, HIV, indicators of liver disease stage, ultrasound screening, stage at HCC diagnosis, and year of HCC diagnosis. Positive value indicates increase in the effect relative to "no treatment".

Incremental cost is calculated as treatment cost minus no treatment cost, adjusted for aforementioned covariates. Positive value indicates increase in cost relative to "no treatment".
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![Efficiency frontier: plot of incremental (A) life years (LYs) and (B) quality‐adjusted life years (QALYs) and costs of curative treatments relative to lowest cost scenario (no treatment). The dotted diagonal line represents the willingness‐to‐pay for health effects (maximum acceptable ceiling ratio). If an intervention lies above the line, it will not be acceptable on cost‐effectiveness grounds.](CAM4-6-2017-g001){#cam41119-fig-0001}

Figure [S2](#cam41119-sup-0001){ref-type="supplementary-material"}A--J (LYs) and Figure [2](#cam41119-fig-0002){ref-type="fig"}A--J (QALYs) show estimates of INB (i.e., ICER estimate) and its 95% CIs as a function of willingness‐to‐pay thresholds. The lowest ICER estimate for TACE plus RFA was \$2,465/QALY gained (95% CI: −\$20,000‐\$36,600/QALY); this means TACE plus RFA is cost‐effective if decision‐makers value \>\$36,600/QALY threshold, but not cost‐effective if decision‐makers value \<−\$20,000/QALY threshold. Alternative ICER estimates in order were: for RFA monotherapy, \$15,553/QALY (95% CI: \$3,500--\$28,500/QALY); RFA + SR, \$48,761/QALY (95% CI: \$35,000--\$67,200/QALY); RFA + LT, \$59,642/QALY (95% CI: \$46,600--\$78,000/QALY); RFA + SR + LT, \$60,602/QALY (95% CI: \$42,600--\$90,000/QALY); SR + LT, \$71,972/QALY (95% CI: \$58,100--\$91,450/QALY); TACE + LT, \$72,941/QALY (95% CI: \$52,700--\$107,600/QALY); LT monotherapy, \$76,738/QALY (95% CI: \$68,400--\$87,200/QALY); SR only, \$79,495/QALY (95% CI: \$65,800--\$98,200/QALY); and TACE + SR, \$217,932/QALY (95% CI: LB \$70,000/QALY; UB undefined) .

![Estimates of incremental net benefit (i.e., incremental cost‐effectiveness ratio, ICER) and its 95% confidence intervals as a function of willingness‐to‐pay threshold for an additional quality‐adjusted life year (QALY); (A) radiofrequency ablation (RFA) monotherapy versus no treatment; (B) surgical resection (SR) monotherapy versus no treatment; (C) liver transplantation (LT) monotherapy versus no treatment; (D) RFA plus SR versus no treatment; (E) RFA plus LT versus no treatment; (F) SR plus LT versus no treatment; (G) TACE plus RFA versus no treatment; (H) TACE plus SR versus no treatment; (I) TACE plus LT versus no treatment; and (J) RFA plus SR plus LT versus no treatment.](CAM4-6-2017-g002){#cam41119-fig-0002}

Figure [3](#cam41119-fig-0003){ref-type="fig"}A and B show CEACs which plot the probability that each treatment strategy is cost‐effective compared with no treatment as a function of willingness‐to‐pay threshold for an additional LY and QALY, respectively. The results showed that if a threshold of \$50,000/LY gained was to be chosen, RFA monotherapy, SR monotherapy, RFA plus SR, RFA plus LT, and TACE plus RFA would have a cost‐effectiveness probability of 99--100% (Table [S5](#cam41119-sup-0005){ref-type="supplementary-material"}); whereas, if \$50,000/QALY gained was to be chosen, RFA monotherapy and TACE plus RFA would have a cost‐effectiveness probability of 99--100% (Table [4](#cam41119-tbl-0004){ref-type="table-wrap"}); and if a threshold of \$100,000/QALY gained was to be chosen, all treatments would have a cost‐effectiveness probability of more than 95% (except TACE plus SR \[12%\], Table [4](#cam41119-tbl-0004){ref-type="table-wrap"}).

![Cost‐effectiveness acceptability curves showing the probability that each curative treatment strategy is cost‐effective compared with no treatment for a given willingness‐to‐pay threshold for an additional (A) life year (LY); and (B) quality‐adjusted life year (QALY).](CAM4-6-2017-g003){#cam41119-fig-0003}

###### 

Estimates of incremental net benefit and probability of cost‐effectiveness of curative treatment strategies for hepatocellular carcinoma compared with no treatment as a function of willingness‐to‐pay threshold per additional QALY over the study period 2002--2010

  *λ* thresholds   Radiofrequency ablation   Surgical resection   Liver transplantation                                                                   
  ---------------- ------------------------- -------------------- ----------------------- ---------------- --------- -------- ----------------- --------- --------
  \$0              −13,698 (5332)            0.005                0.0051                  −81,536 (4592)   \<0.001   0.0001   −160,428 (5568)   \<0.001   0.0001
  \$1,000          −12,817 (5319)            0.008                0.008                   −80,511 (4582)   \<0.001   0.0001   −158,337 (5554)   \<0.001   0.0001
  \$10,000         −4892 (5300)              0.178                0.1781                  −71,287 (4580)   \<0.001   0.0001   −139,516 (5534)   \<0.001   0.0001
  \$20,000         3915 (5487)               0.238                0.7622                  −61,037 (4755)   \<0.001   0.0001   −118,605 (5731)   \<0.001   0.0001
  \$30,000         12,721 (5872)             0.015                0.9849                  −50,787 (5099)   \<0.001   0.0001   −97,693 (6138)    \<0.001   0.0001
  \$40,000         21,527 (6420)             \<0.001              0.9996                  −40,537 (5580)   \<0.001   0.0001   −76,781 (6717)    \<0.001   0.0001
  \$50,000         30,333 (7093)             \<0.001              1.0000                  −30,288 (6167)   \<0.001   0.0001   −55,870 (7427)    \<0.001   0.0001
  \$60,000         39,139 (7859)             \<0.001              1.0000                  −20,038 (6832)   0.002     0.0017   −34,958 (8235)    \<0.001   0.0001
  \$70,000         47,945 (8693)             \<0.001              1.0000                  −9788 (7555)     0.098     0.0976   −14,047 (9114)    0.062     0.0617
  \$80,000         56,751 (9578)             \<0.001              1.0000                  462 (8320)       0.478     0.5221   6865 (10,047)     0.247     0.7528
  \$90,000         65,557 (10,501)           \<0.001              1.0000                  10,711 (9117)    0.120     0.8800   27,777 (11,019)   0.006     0.9942
  \$100,000        74,363 (11,452)           \<0.001              1.0000                  20,961 (9938)    0.017     0.9826   48,688 (12,020)   \<0.001   1.0000

  *λ* thresholds   Radiofrequency ablation plus surgical resection   Radiofrequency ablation plus liver transplantation   Surgical resection plus liver transplantation                                                                       
  ---------------- ------------------------------------------------- ---------------------------------------------------- ----------------------------------------------- ------------------ --------- -------- ------------------- --------- --------
  \$0              −71,514 (8749)                                    \<0.001                                              0.0001                                          −112,421 (9864)    \<0.001   0.0001   −173,510 (11,812)   \<0.001   0.0001
  \$1,000          −70,046 (8730)                                    \<0.001                                              0.0001                                          −11,0538 (9842)    \<0.001   0.0001   −171,100 (11,789)   \<0.001   0.0001
  \$10,000         −56,830 (8726)                                    \<0.001                                              0.0001                                          −93,589 (9836)     \<0.001   0.0001   −149,406 (11,800)   \<0.001   0.0001
  \$20,000         −42,146 (9063)                                    \<0.001                                              0.0001                                          −74,757 (10,214)   \<0.001   0.0001   −125,302 (12,268)   \<0.001   0.0001
  \$30,000         −27,462 (9721)                                    0.002                                                0.0024                                          −55,926 (10,957)   \<0.001   0.0001   −101,197 (13,166)   \<0.001   0.0001
  \$40,000         −12,778 (10,642)                                  0.115                                                0.1149                                          −37,094 (11,998)   0.001     0.0010   −77,093 (14,414)    \<0.001   0.0001
  \$50,000         1905 (11,764)                                     0.436                                                0.5644                                          −18,262 (13,266)   0.0843    0.0843   −52,989 (15,929)    \<0.001   0.0005
  \$60,000         16,589 (13,035)                                   0.102                                                0.8985                                          570 (14,703)       0.48455   0.5155   −28,885 (17,644)    0.051     0.0508
  \$70,000         31,273 (14,415)                                   0.015                                                0.9850                                          19,402 (16,264)    0.11645   0.8836   −4781 (19,505)      0.403     0.4032
  \$80,000         45,957 (15,877)                                   0.002                                                0.9981                                          38,233 (17,916)    0.0164    0.9836   19,324 (21,474)     0.184     0.8159
  \$90,000         60,641 (17,399)                                   \<0.001                                              0.9998                                          57,065 (19,638)    0.00185   0.9982   43,428 (23,524)     0.032     0.9676
  \$100,000        75,325 (18,968)                                   \<0.001                                              1.0000                                          75,897 (21,411)    0.0002    0.9998   67,532 (25,637)     0.004     0.9958

  *λ* thresholds   TACE plus radiofrequency ablation   TACE plus surgical resection   TACE plus liver transplantation                                                                       
  ---------------- ----------------------------------- ------------------------------ --------------------------------- ------------------ --------- -------- ------------------- --------- --------
  \$0              −2262 (13,639)                      0.434                          0.5659                            −95,930 (20,116)   \<0.001   0.0001   −132,378 (13,697)   \<0.001   0.0001
  \$1,000          −1326 (13,611)                      0.461                          0.5388                            −95,491 (20,076)   \<0.001   0.0001   −130,562 (13,668)   \<0.001   0.0001
  \$10,000         7094 (13,612)                       0.301                          0.6989                            −91,538 (20,096)   \<0.001   0.0001   −114,221 (13,670)   \<0.001   0.0001
  \$20,000         16,449 (14,146)                     0.122                          0.8776                            −87,145 (20,893)   \<0.001   0.0001   −96,065 (14,207)    \<0.001   0.0001
  \$30,000         25,804 (15,183)                     0.045                          0.9554                            −82,753 (22,420)   \<0.001   0.0001   −77,909 (15,248)    \<0.001   0.0001
  \$40,000         35,160 (16,628)                     0.017                          0.9828                            −78,360 (24,541)   \<0.001   0.0007   −59,752 (16,699)    \<0.001   0.0002
  \$50,000         44,515 (18,386)                     0.008                          0.9923                            −73,968 (27,118)   0.003     0.0032   −41,596 (18,463)    0.012     0.0122
  \$60,000         53,870 (20,376)                     0.004                          0.9959                            −69,575 (30,032)   0.010     0.0103   −23,439 (20,461)    0.126     0.1260
  \$70,000         63,226 (22,536)                     0.003                          0.9975                            −65,182 (33,196)   0.025     0.0248   −5283 (22,629)      0.408     0.4077
  \$80,000         72,581 (24,822)                     0.002                          0.9983                            −60,790 (36,544)   0.048     0.0481   12,874 (24,924)     0.303     0.6973
  \$90,000         81,936 (27,203)                     0.001                          0.9987                            −56,397 (40,030)   0.079     0.0795   31,030 (27,314)     0.128     0.8721
  \$100,000        91,292 (29,655)                     0.001                          0.9990                            −52,005 (43,622)   0.117     0.1166   49,187 (29,775)     0.049     0.9508

  *λ* thresholds   Radiofrequency ablation plus surgical resection plus liver transplantation             
  ---------------- ---------------------------------------------------------------------------- --------- --------
  \$0              −164,675 (20,178)                                                            \<0.001   0.0001
  \$1,000          −161,956 (20,138)                                                            \<0.001   0.0001
  \$10,000         −137,487 (20,158)                                                            \<0.001   0.0001
  \$20,000         −110,300 (20,961)                                                            \<0.001   0.0001
  \$30,000         −83,113 (22,500)                                                             \<0.001   0.0001
  \$40,000         −55,925 (24,636)                                                             0.012     0.0116
  \$50,000         −28,738 (27,230)                                                             0.146     0.1457
  \$60,000         −1551 (30,164)                                                               0.480     0.4795
  \$70,000         25,637 (33,348)                                                              0.221     0.779
  \$80,000         52,824 (36,717)                                                              0.075     0.925
  \$90,000         80,011 (40,225)                                                              0.023     0.977
  \$100,000        107,199 (43,838)                                                             0.007     0.993

*λ*, willingness‐to‐pay; INB, incremental net benefit; SE, standard error.

One‐sided *P*‐value.
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Sensitivity analysis {#cam41119-sec-0014}
--------------------

Sensitivity analysis according to the pooled lower and upper bound health state utilities of disease stage from published literature showed that TACE plus RFA, RFA monotherapy, and RFA + SR dual treatment appeared to be acceptable compared to no treatment, similar to base case (Fig. [S3](#cam41119-sup-0003){ref-type="supplementary-material"}A and B). A sensitivity analysis of excluding HCC stage IV appeared robust to the base case (stage IV was lumped with stage III) relating to the incremental effects (LYs and QALYs) and costs, and ICER of curative treatments relative to no treatment (Fig. [S4](#cam41119-sup-0003){ref-type="supplementary-material"}A and B).

Discussion {#cam41119-sec-0015}
==========

This study evaluated the real‐world cost‐effectiveness of potentially curative treatments compared with no treatment among patients diagnosed with HCC over a 9‐year study time frame from a healthcare payer\'s perspective in Ontario, Canada\'s most populated province with approximately 13.6 million people as of year 2013. We note that during this time period, no new curative therapies have become available. Compared with no treatment, the adjusted incremental benefit of LT‐related treatments are estimated to yield more units of QALYs than RFA or SR treatments, but are more costly. ICERs of TACE plus RFA dual treatment (i.e., major primary RFA; average \$2,465, 95% CI: −\$20,000--\$36,600/QALY gained) and RFA monotherapy (average \$15,553, 95% CI: \$3,500--\$28,500/QALY gained) are below the commonly cited thresholds of \$50,000/QALY [41](#cam41119-bib-0041){ref-type="ref"}. Interventions costing less than \$50,000/QALY are often considered cost‐effective [42](#cam41119-bib-0042){ref-type="ref"}, but oncologists commonly endorse higher thresholds [43](#cam41119-bib-0043){ref-type="ref"}. The CEACs show that if a threshold of \$50,000/QALY gained is to be chosen, RFA monotherapy and TACE plus RFA would have a cost‐effectiveness probability of 99--100%. If a threshold of \$100,000/QALY gained is to be chosen, all treatments would have a cost‐effectiveness probability of more than 95% (except TACE plus SR).

Historically, percutaneous RFA was widely used for local control of small unresectable HCC including those patients who could not tolerate SR but it is increasingly being used as first‐line therapy for patients with amenable lesions [9](#cam41119-bib-0009){ref-type="ref"}. Based on published papers, the combination treatment of TACE and RFA seems to be a safe and effective treatment strategy for patients with early‐ or intermediate‐stage HCC [44](#cam41119-bib-0044){ref-type="ref"}, [45](#cam41119-bib-0045){ref-type="ref"}. In patients included in the waiting list for a LT, tumors are often treated as a "bridge" to transplant while waiting for an organ to become available because of the risk of tumor progression. RFA is widely used as a "bridge" to transplantation in order to avoid this progression [46](#cam41119-bib-0046){ref-type="ref"}. This analysis was able to include patients who may have undergone palliative treatment (i.e., TACE) as a bridge to LT.

A few other studies analyzed the cost‐effectiveness of two potentially curative treatment strategies in early‐stage HCC within the Milan criteria using Markov cohort models. Cucchetti et al. compared SR with RFA and found that in the presence of two or three nodules ≤3 cm, RFA is more cost‐effective than resection; for single larger early‐stage HCC, SR is cost‐effective at a willingness‐to‐pay largely acceptable in the oncologic setting [27](#cam41119-bib-0027){ref-type="ref"}. Lim et al. compared SR with LT and found that in patients with HCC within the Milan criteria and Child‐Pugh A/B cirrhosis, SR is more cost‐effective than cadaveric LT across three different costing scenarios: the USA, Switzerland, and Singapore [28](#cam41119-bib-0028){ref-type="ref"}. Our findings highlight the important implications for identification and measurement of differential benefits, costs, and cost‐effectiveness of alternative HCC curative treatments in order to evaluate whether particular healthcare technologies are providing good value for money in the real‐world within the context of an organized healthcare system.

HCC is a rapidly rising disease and many patients who develop HCC present late which becomes an incurable advanced‐stage disease. The biggest limitation to treating HCC is the function of the underlying liver and the stage of first HCC diagnosis. It is evident that patients with HCC receiving treatments might appear fairly different with regard to clinical and tumor features that are known to affect prognosis [47](#cam41119-bib-0047){ref-type="ref"}. Patients might not be considered suitable for surgery because of liver dysfunction and/or portal hypertension, as well as the presence of comorbidities or advanced age contraindicating general anesthesia [47](#cam41119-bib-0047){ref-type="ref"}. Screening and surveillance programs for early detection of HCC and keeping track of the outcomes for quality assurance are needed [48](#cam41119-bib-0048){ref-type="ref"}. Given the increasing and high mortality rate associated with HCC, investments and healthcare resources at existing regional cancer centers should be enhanced to facilitate the multidisciplinary care to mitigate the impact of the disease [14](#cam41119-bib-0014){ref-type="ref"}, [49](#cam41119-bib-0049){ref-type="ref"}. Thus, treating liver disease is a priority and is needed to act to protect the health and well‐being of Canadians of all ages. Recommendations to improve the control of HCC in Canada include healthcare providers to identify, offer testing, and counsel people at risk for HCC such as alcohol‐and non‐alcohol‐induced liver disease, cirrhosis, diabetes, obesity, smoking, [50](#cam41119-bib-0050){ref-type="ref"}, [51](#cam41119-bib-0051){ref-type="ref"}, [52](#cam41119-bib-0052){ref-type="ref"}, [53](#cam41119-bib-0053){ref-type="ref"}, [54](#cam41119-bib-0054){ref-type="ref"} and HIV coinfection [55](#cam41119-bib-0055){ref-type="ref"}, in particular, marginalized groups of people. Furthermore, patients need easier access to treatments to reduce the chance of progression to liver cancer.

The net benefit framework can clearly demonstrate how different the ICERs are when adjusted or not adjusted for covariates. The advantage of this is that influential covariates can be adjusted for in the regression model to obtain a more accurate INB [16](#cam41119-bib-0016){ref-type="ref"}. This NBR found several covariates associated with INB (*P *\< 0.05), including age group and sex (from *λ* \$10,000 to *λ* \$100,000), income quintile (from *λ* \$0 to *λ* \$25,000), Charlson--Deyo comorbidity index, cirrhosis, and viral hepatitis + cirrhosis (from *λ* \$0 to *λ* \$100,000), ALD + cirrhosis, decompensated cirrhosis, and routine screening (i.e., one or more ultrasound screening annually for 2 years before HCC diagnosis) (from *λ* \$0 to *λ* \$50,000), and HIV diagnosis and year of HCC diagnosis (from *λ* \$25,000 to *λ* \$100,000). The strategy with the largest incremental benefit while still being cost‐effective may be the preferred strategy.

This study is meant to be a cost‐effectiveness analysis taken from the perspective of the healthcare payer on a population‐level (and not an individual‐level decision‐analysis to aid individual decision‐making). This helps payers understand the trade‐offs of cost and benefits of the various curative intent therapies. This information can help with priority‐setting to allow payers maximize health outcomes if they are faced with finite budget. Given the rising cost of therapies, especially with the rising cost of new expensive drugs, this study can help payers understand the value for money of the curative intent therapies in the context of demands to fund newer but palliative expensive drugs.

There are a number of limitations in this study that should be considered. Using a 9‐year observation period may result in an underestimation of the true benefits of HCC curative treatment. If HCC curative treatment does have an impact on the long‐term survival, the full impact will not be observed within the 9‐year observation period. Although additional work such as building a mathematical model is not within the scope of this study, data collected can be utilized to support future modeling studies. Other limitations include the stage of HCC at treatment; clearly, smaller lesions detected early by regular serial ultrasound surveillance, will be associated with lower costs and better survival, than more advanced lesions requiring multi‐modal treatment or LT. From our analysis, it can be inferred that ultrasound surveillance programs may be associated with lower costs and better cost‐effectiveness if small lesions amenable to RFA only, can be diagnosed. This may have an effect but overall, there is only 11.8% receiving regular ultrasound screening. Patients who may have undergone RFA at laparotomy (i.e., because of location of the HCC) may have been coded as dual therapy or SR clinically.

Conclusions {#cam41119-sec-0016}
===========

From our analysis, compared with no treatment, TACE plus RFA dual treatment or RFA monotherapy appears to be the most cost‐effective modality with lowest ICER value if a threshold of \$50,000/QALY gained was to be chosen, but this is generalizable only to those who are diagnosed with early HCC lesions. In order to achieve optimal cost‐effectiveness of HCC treatment with curative intent, patients at risk of HCC must be diagnosed early (i.e., via regular ultrasound surveillance) and referred for treatment in a timely manner before HCC disease progression requires more advanced curative treatment (i.e., SR, LT, etc.) that is associated with greater healthcare costs and less favorable cost‐effectiveness calculations.
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**Figure S1.** Selection criteria for the study sample.
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**Figure S2.** Estimates of incremental net benefit (i.e., incremental cost‐effectiveness ratio, ICER) and its 95% confidence intervals as a function of willingness‐to‐pay threshold for an additional life year (LY); (S2A) radiofrequency ablation (RFA) monotherapy versus no treatment; (S2B) surgical resection (SR) monotherapy versus no treatment; (S2C) liver transplantation (LT) monotherapy versus no treatment; (S2D) RFA plus SR versus no treatment; (S2E) RFA plus LT versus no treatment; (S2F) SR plus LT versus no treatment; (S2G) TACE plus RFA versus no treatment; (S2H) TACE plus SR versus no treatment; (S2I) TACE plus LT versus no treatment; and (S2J) RFA plus SR plus LT versus no treatment.
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**Figure S3.** Efficiency frontier: plot of incremental quality‐adjusted life years (QALYs) and costs of curative treatments relative to lowest cost scenario (no treatment): Sensitivity analysis according to (S3A) lower bound and (S3B) upper bound of pooled mean health state utilities of disease stage from published literature. The dotted diagonal line represents the willingness‐to‐pay for health effects (maximum acceptable ceiling ratio). If an intervention lies above the line, it will not be acceptable on cost‐effectiveness grounds.
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**Figure S4.** Efficiency frontier: Efficiency frontier: plot of incremental (A) life years (LYs) and (B) quality‐adjusted life years (QALYs) and costs of curative treatments relative to lowest cost scenario (no treatment): Sensitivity analysis of excluding HCC stage IV.
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**Tables S1.** ICD‐9 and ICD‐10 codes for patients diagnosed with diabetes, HIV, and liver disease stage.
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**Table S3.** Estimation of utilities for noncirrhosis.

**Table S4.** Baseline characteristics of patients with hepatocellular carcinoma, 2002--2010.

**Table S5.** Estimates of incremental net benefit and probability of cost‐effectiveness of curative treatment strategies for hepatocellular carcinoma compared with no treatment as a function of willingness‐to‐pay threshold per additional life year over the study period 2002--2010.
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